A Phase 3 interventional study of Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1) and Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2) in Serogroup B Meningococcal Meningitis, sponsored by Novartis Vaccines. Completed at 66 sites in 5 countries. Open to participants aged 55 Days to 89 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-10-10.
Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Meningitis, Meningococcal by Novartis — none open to participants now, none under way, none of them phase 3. Meningitis, Meningococcal · Novartis.
Among the 32 studies in Meningitis, Meningococcal by Novartis, this one is the 2nd largest by enrollment of the 30 interventional ones that give a count, is one of 2 that started in 2008, is one of 19 in phase 3, and was the 9th registered.
125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.
Browse Meningitis, Meningococcal studies →None of the 32 studies in Meningitis, Meningococcal by Novartis is open now. The open studies under Meningitis, Meningococcal, anywhere →
Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 55 Days to 89 Days · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 10 · Phase 3 21 · Phase 4 1
First in 2005; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,630 is above the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.
Median enrollment 707 across the 30 interventional studies, 27,895 across the 2 observational. Of the 32 that completed or were terminated, 28 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Vaccines, one of the names counted as Novartis. Under that name alone:
Novartis Vaccines is the lead sponsor of 165 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 32 studies in Meningitis, Meningococcal by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The proposed study was aimed to assess the immunogenicity, safety, tolerability and lot to lot consistency of 3 lots of Novartis Meningococcal B vaccine when given concomitantly with routine infant vaccines.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received one injection of rMenB+OMV NZ (Lot 1) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.
Biological: Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1)
Subjects received one injection of rMenB+OMV NZ (Lot 2) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.
Biological: Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2)
Subjects received one injection of rMenB+OMV NZ (Lot 3) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.
Biological: Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3)
Subjects received the routinely administered infant vaccines at 2, 4, 6 months of age.
Biological: Infanrix Hexa · Biological: Prevenar
Subjects received the routinely administered infant vaccines and Men C vaccine at 2, 4 and 6 months of age.
Biological: Infanrix Hexa · Biological: Menjugate · Biological: Prevenar
One dose of rMenB Lot concomitantly with the routinely administered infant vaccines
One dose of rMenB concomitantly with the routinely administered infant vaccines
One dose of rMenB concomitantly with the routinely administered infant vaccines
Routine vaccination
One dose of the routinely administered infant vaccines + MenC vaccine
Routine vaccination
The Geometric Mean Human Serum Bactericidal Activity (hSBA) Titers After Three Doses of rMenB+OMV NZ Vaccination
The hSBA antibody titer responses, one month after receiving the third vaccination of rMenB+OMV NZ vaccination, are reported as geometric mean titers (GMTs).
Time frame: one month after the third vaccination
The Percentages of Subjects With hSBA Titer ≥1:5 After Receiving Three Doses of rMenB+OMV Vaccination (3 Lots Combined)
The immunogenicity was assessed in terms of the percentages of subjects who had received the three doses of rMenB+OMV NZ (3 lots combined) given concomitantly with routine infant vaccinations and percentages of subjects who received only the routine infant vaccinations as measured by hSBA titer ≥1:5 following rMenB+OMV NZ vaccinations one month after the third vaccination is reported.
Time frame: one month after the third vaccination
The Percentages of Subjects With hSBA Titer ≥1:5 After Receiving Three Doses of rMenB+OMV Vaccination (From 3 Lots)
The immunogenicity was evaluated to assess the consistency of the immune response from three lots of rMenB+OMV NZ in terms of percentage of subjects as measured by hSBA titer ≥1:5 when given to healthy infants at 2, 4, and 6 months of age, at 1 month after the third vaccination.
Time frame: 1 month after the third vaccination
Geometric Mean Human Serum Bactericidal Activity Titers After the Routine Vaccination Without rMenB OMV NZ
The immunogenicity was assessed in terms of prevalence of meningococcal B antibodies as measured by the hSBA, at baseline and at one month after the third vaccination, in the subjects that received routine infant vaccines without rMenB+OMV NZ.
Time frame: 1 Month after the third vaccination
Geometric Mean Concentrations After Three Doses of rMenB+OMV NZ Vaccination (Against the 287-953 Antigen)
The immunogenicity was evaluated to characterize the immune response against vaccine antigen 287-953, as measured by ELISA at one month after third vaccination.
Time frame: 1 month after third vaccination
Geometric Mean Concentrations for Antigens (Pertussis Components) for the Routine Vaccinations
Immunogenicity of the pertussis components (PT, FHA, pertactin) of DTPa-HBV-IPV when given concomitantly with rMenB and PCV7 would be considered non-inferior to that of the routine vaccines given alone if the lower limit of the two-sided CI for the ratio of GMCs one month after third vaccination.
Time frame: 1 month after third vaccination
Percentages of Subjects With Antibody Response Against the Routine Antigens
The immunogenicity of routine infant vaccines when given concomitantly with rMenB+OMV NZ at 2, 4, and 6 months of age and of the routine infant vaccines given without rMenB+OMV NZ at 1 month after third vaccination with B pertussis, diptheria and tetanus toxoid, H influenza type b, Hepatitis B antigens was measured by ELISA (Enzyme-linked immunosorbent assay) and for polio type 1, type 2 and type 3 by neutralization test (NT)(\>=1:8). Diptheria and Tetanus: primary endpoint ELISA \>=0.1 (international unit -IU) IU/mL and the secondary endpoint is ELISA\>=1.0 IU/mL. HepB (HBV):primary endpoint ELISA \>=10 mU/mL. PRP-T: primary endpoint ≥ 0.15 mcg/mL and ≥ 1.00 mcg/mL.PNC \>=0.35 mcg/ml
Time frame: 1 Month after third vaccination
Percentages of Subjects With Fourfold Increase in Antibody Concentrations Against the Routine Antigens
Immunogenicity was assessed in terms of the percentages of subjects with fourfold increase in antibody concentrations against the routine pertussis antigens FHA (Filamentous Hemagglutinin), Pertactin and PT (Pertussis Toxoid).
Time frame: 5 months
Percentages of Subjects With Fourfold Rise in hSBA Titers After Three Doses of rMenB+OMV NZ Vaccination
Immunogenicity was assessed in terms of the percentages of subjects with fourfold rise in hSBA titers after the three doses of rMenB+OMV NZ (lot 1 or lot 2 or lot 3) vaccination at 2, 4 and 6 months of age.
Time frame: 1 Month after third vaccination
Percentage of Subjects With hSBA Titers ≥1:8
Immunogenicity was assessed in terms of the percentages of subjects achieving hSBA titers ≥1:8 at one month after third vaccination with rMenB (lot 1 or lot 2 or lot 3) against the three vaccine strains.
Time frame: 1 month after third vaccination
Number of Subjects Reporting Solicited Adverse Events After Receiving Three Doses of rMenB+OMV NZ Vaccine
The safety and tolerability of three doses of rMenB+OMV NZ when given concomitantly with routine infant vaccines at 2, 4 and 6 months of age was assessed by the number of subjects reporting solicited local and systemic adverse events.
Time frame: upto 7 days after any vaccination
16 sites in Finland, 28 sites in the Czech Republic, 13 sites in Germany, 6 sites in Austria, 7 sites in Italy.
| Milestone | rMenB Lot1 | rMenB Lot2 | rMenB Lot3 | Routine | MenC+ Routine |
|---|---|---|---|---|---|
| Started | 833 | 828 | 820 | 659 | 490 |
| Completed | 810 | 795 | 792 | 645 | 457 |
| Not completed | 23 | 33 | 28 | 14 | 33 |
| Withdrew: Ae or death | 7 | 7 | 6 | 7 | 1 |
| Withdrew: Withdrawal by subject | 7 | 15 | 15 | 5 | 9 |
| Withdrew: Lost to follow-up | 9 | 9 | 7 | 1 | 21 |
| Withdrew: Protocol violation | 0 | 2 | 0 | 1 | 2 |
The hSBA antibody titer responses, one month after receiving the third vaccination of rMenB+OMV NZ vaccination, are reported as geometric mean titers (GMTs).
| Titers | rMenB Lot1 | rMenB Lot2 | rMenB Lot3 |
|---|---|---|---|
| 44/76-SL strain (Baseline) | 1.21 (1.14 to 1.29) | 1.19 (1.12 to 1.27) | 1.19 (1.12 to 1.27) |
| 44/76-SL strain one month after 3rd vaccination | 87 (80 to 95) | 98 (90 to 106) | 85 (78 to 93) |
| 5/99 strain (Baseline) | 1.21 (1.14 to 1.3) | 1.2 (1.12 to 1.28) | 1.21 (1.13 to 1.29) |
| 5/99 strain one month after 3rd vaccination | 598 (550 to 651) | 681 (626 to 741) | 607 (558 to 661) |
| NZ98/254 strain (Baseline) | 1.03 (1 to 1.06) | 1.06 (1.03 to 1.1) | 1.04 (1 to 1.07) |
| one month after 3rd vaccination | 15 (13 to 17) | 14 (12 to 16) | 15 (14 to 17) |
The immunogenicity was assessed in terms of the percentages of subjects who had received the three doses of rMenB+OMV NZ (3 lots combined) given concomitantly with routine infant vaccinations and percentages of subjects who received only the routine infant vaccinations as measured by hSBA titer ≥1:5 following rMenB+OMV NZ vaccinations one month after the third vaccination is reported.
| Percentages of subjects | rMenB All | Routine |
|---|---|---|
| 44/76-SL strain (Baseline) | 3 (2 to 4) | 3 (1 to 8) |
| 44/76-SL strain-1 Month after 3rd vaccination | 100 (99 to 100) | 3 (1 to 7) |
| 5/99 strain (Baseline) | 4 (3 to 5) | 7 (3 to 13) |
| 5/99 strain-1 Month after 3rd vaccination | 100 (99 to 100) | 2 (0 to 6) |
| NZ98/254 strain (Baseline) | 1 (1 to 2) | 1 (0.021 to 5) |
| 1 Month after 3rd vaccination | 84 (82 to 86) | 2 (0 to 6) |
The immunogenicity was evaluated to assess the consistency of the immune response from three lots of rMenB+OMV NZ in terms of percentage of subjects as measured by hSBA titer ≥1:5 when given to healthy infants at 2, 4, and 6 months of age, at 1 month after the third vaccination.
| Percentages of subjects | rMenB Lot1 | rMenB Lot2 | rMenB Lot3 | Routine |
|---|---|---|---|---|
| 44/76-SL Baseline | 4 (2 to 6) | 2 (1 to 4) | 3 (2 to 6) | 3 (1 to 8) |
| 44/76-SL-1 Month after 3rd vaccination | 100 (99 to 100) | 100 (99 to 100) | 99 (98 to 100) | 3 (1 to 7) |
| 5/99 Baseline | 3 (2 to 5) | 4 (3 to 7) | 4 (2 to 7) | 7 (3 to 13) |
| 5/99-1 Month after 3rd vaccination | 100 (99 to 100) | 100 (99 to 100) | 99 (98 to 100) | 2 (0 to 6) |
| NZ 98/254 Baseline | 1 (0 to 2) | 2 (1 to 4) | 1 (0 to 2) | 1 (0.021 to 5) |
| 1 Month after 3rd vaccination | 84 (80 to 88) | 81 (77 to 85) | 85 (81 to 89) | 2 (0 to 6) |
The immunogenicity was assessed in terms of prevalence of meningococcal B antibodies as measured by the hSBA, at baseline and at one month after the third vaccination, in the subjects that received routine infant vaccines without rMenB+OMV NZ.
| Titers | rMenB All | Routine |
|---|---|---|
| 44/76 Strain (Baseline) | 1.15 (1.12 to 1.19) | 1.12 (1.04 to 1.22) |
| 44/76 Strain-1 Month after third vaccination | 91 (87 to 95) | 1.2 (1.1 to 1.31) |
| 5/99 Strain (Baseline) | 1.18 (1.14 to 1.22) | 1.21 (1.1 to 1.33) |
| 5/99 Strain-1 Month after third vaccination | 635 (606 to 665) | 1.06 (0.97 to 1.17) |
| NZ98/254 (Baseline) | 1.05 (1.03 to 1.07) | 1.01 (0.99 to 1.04) |
| 1 Month after third vaccination | 14 (13 to 15) | 1.04 (0.98 to 1.11) |
The immunogenicity was evaluated to characterize the immune response against vaccine antigen 287-953, as measured by ELISA at one month after third vaccination.
| IU/mL | rMenB Lot1 | rMenB Lot2 | rMenB Lot3 | rMenB All | Routine |
|---|---|---|---|---|---|
| Baseline | 22 (21 to 23) | 22 (21 to 22) | 22 (21 to 23) | 22 (21 to 22) | 21 (20 to 21) |
| 1 Month after 3rd vaccination | 3149 (2960 to 3352) | 3484 (3270 to 3712) | 3103 (2915 to 3304) | 3370 (3270 to 3472) | 22 (21 to 23) |
Immunogenicity of the pertussis components (PT, FHA, pertactin) of DTPa-HBV-IPV when given concomitantly with rMenB and PCV7 would be considered non-inferior to that of the routine vaccines given alone if the lower limit of the two-sided CI for the ratio of GMCs one month after third vaccination.
| IU/mL | rMenB All | Routine |
|---|---|---|
| FHA (Baseline) | 9.98 (8.78 to 11) | 9.28 (8.17 to 11) |
| 1 Month post 3rd vaccination; FHA | 123 (114 to 133) | 147 (136 to 158) |
| Pertactin (Baseline) | 6.3 (5.52 to 7.17) | 5.36 (4.71 to 6.11) |
| 1 Month post 3rd vaccination; Pertactin | 107 (97 to 119) | 139 (126 to 155) |
| PT (Baseline) | 2.82 (2.68 to 2.96) | 2.82 (2.68 to 2.96) |
| 1 Month post 3rd vaccination; PT | 41 (37 to 44) | 51 (46 to 55) |
The immunogenicity of routine infant vaccines when given concomitantly with rMenB+OMV NZ at 2, 4, and 6 months of age and of the routine infant vaccines given without rMenB+OMV NZ at 1 month after third vaccination with B pertussis, diptheria and tetanus toxoid, H influenza type b, Hepatitis B antigens was measured by ELISA (Enzyme-linked immunosorbent assay) and for polio type 1, type 2 and type 3 by neutralization test (NT)(\>=1:8). Diptheria and Tetanus: primary endpoint ELISA \>=0.1 (international unit -IU) IU/mL and the secondary endpoint is ELISA\>=1.0 IU/mL. HepB (HBV):primary endpoint ELISA \>=10 mU/mL. PRP-T: primary endpoint ≥ 0.15 mcg/mL and ≥ 1.00 mcg/mL.PNC \>=0.35 mcg/ml
| Percentages Of Subjects | rMenB All | Routine |
|---|---|---|
| Anti-DiphtheriaToxin ≥0.1IU/mL(Baseline) | 38 (32 to 44) | 38 (32 to 45) |
| 1 Month post third vaccination;anti-D | 100 (98 to 100) | 100 (98 to 100) |
| Anti-DiphtheriaToxin ≥1.0 IU/mL(Baseline) | 2 (1 to 5) | 2 (1 to 5) |
| 1 Month post third vaccination, anti-D≥1.0 IU/mL | 80 (75 to 85) | 86 (81 to 90) |
| Anti-TetanusToxin ≥0.1 IU/mL(Baseline) | 93 (88 to 96) | 95 (91 to 97) |
| 1 Month post third vaccination;anti-T | 100 (98 to 100) | 100 (98 to 100) |
| Anti-Tetanus Toxin ≥1.0 IU/mL(Baseline) | 24 (18 to 30) | 27 (22 to 33) |
| 1 Month after third vaccination,anti-T≥1.0 IU/mL | 91 (86 to 94) | 95 (91 to 97) |
| Polio 1 ≥1:8 (Baseline) | 75 (69 to 80) | 72 (66 to 77) |
| 1 Month post third vaccination;Polio 1 | 95 (92 to 98) | 97 (94 to 99) |
| Polio 2 (Baseline) | 68 (62 to 74) | 69 (63 to 74) |
| 1 Month post third vaccination;Polio 2 | 88 (84 to 92) | 94 (90 to 97) |
| Polio 3 (Baseline) | 48 (41 to 54) | 49 (42 to 55) |
| 1 Month post third vaccination;Polio 3 | 97 (94 to 99) | 98 (95 to 99) |
| HBV ≥10 mIU/mL (Baseline) | 22 (17 to 28) | 15 (10 to 20) |
| 1 Month post third vaccination;HBV | 98 (95 to 99) | 100 (99 to 100) |
| Anti-PRP (HIB) ≥ 0.15 μg/mL(Baseline) | 54 (47 to 60) | 55 (49 to 62) |
| 1 Month post 3rd vaccination;anti-PRP ≥ 0.15 | 99 (97 to 100) | 100 (98 to 100) |
| Anti-PRP (HIB) ≥ 1.0 μg/mL (Baseline) | 12 (9 to 17) | 10 (7 to 15) |
| 1 Month post third vaccination;anti-PRP ≥ 1.0 | 79 (73 to 84) | 79 (73 to 84) |
| PnC4 ≥0.35μg/mL (Baseline) | 2 (0 to 4) | 2 (1 to 5) |
| 1 Month post third vaccination;PnC4 | 98 (95 to 99) | 100 (98 to 100) |
| PnC 6B ≥0.35μg/mL (Baseline) | 14 (10 to 19) | 16 (12 to 22) |
| 1 Month post third vaccination;PnC 6B | 90 (85 to 93) | 88 (83 to 92) |
| PnC 9V ≥0.35μg/mL (Baseline) | 4 (2 to 7) | 3 (1 to 6) |
| 1 Month post third vaccination;PnC 9V | 100 (98 to 100) | 100 (98 to 100) |
| PnC 14 ≥0.35μg/mL (Baseline) | 33 (27 to 39) | 38 (31 to 44) |
| 1 Month post third vaccination;PnC 14 | 96 (93 to 98) | 97 (94 to 99) |
| PnC 18C ≥0.35μg/mL (Baseline) | 10 (7 to 15) | 17 (12 to 22) |
| 1 Month post third vaccination;PnC 18 | 98 (96 to 100) | 99 (97 to 100) |
| PnC 19F ≥0.35μg/mL (Baseline) | 20 (15 to 26) | 21 (16 to 27) |
| 1 Month post third vaccination;PnC 19 | 96 (93 to 98) | 96 (93 to 98) |
| PnC 23F ≥0.35μg/mL (Baseline) | 16 (12 to 21) | 22 (17 to 28) |
| 1 Month post 3rd vaccination;PnC 23F | 92 (88 to 95) | 95 (92 to 97) |
Immunogenicity was assessed in terms of the percentages of subjects with fourfold increase in antibody concentrations against the routine pertussis antigens FHA (Filamentous Hemagglutinin), Pertactin and PT (Pertussis Toxoid).
| Percentages of Subjects | rMenB All | Routine |
|---|---|---|
| FHA | 84 (79 to 88) | 87 (82 to 91) |
| Pertactin | 79 (73 to 84) | 88 (84 to 92) |
| PT | 92 (88 to 95) | 95 (91 to 97) |
Immunogenicity was assessed in terms of the percentages of subjects with fourfold rise in hSBA titers after the three doses of rMenB+OMV NZ (lot 1 or lot 2 or lot 3) vaccination at 2, 4 and 6 months of age.
| Percentages of Subjects | rMenB Lot1 | rMenB Lot2 | rMenB Lot3 | rMenB All | Routine |
|---|---|---|---|---|---|
| 44/76-SL | 99 (97 to 100) | 100 (99 to 100) | 98 (97 to 99) | 99 (98 to 100) | 1 (0.023 to 5) |
| 5/99 | 100 (99 to 100) | 100 (99 to 100) | 99 (98 to 100) | 100 (99 to 100) | 2 (0 to 6) |
| NZ98/254 | 70 (66 to 75) | 69 (64 to 74) | 75 (70 to 79) | 71 (69 to 74) | 1 (0.022 to 5) |
Immunogenicity was assessed in terms of the percentages of subjects achieving hSBA titers ≥1:8 at one month after third vaccination with rMenB (lot 1 or lot 2 or lot 3) against the three vaccine strains.
| Percentages of subjects | rMenB Lot1 | rMenB Lot2 | rMenB Lot3 | rMenB All | Routine |
|---|---|---|---|---|---|
| 44/76-SL (Baseline) | 2 (1 to 4) | 2 (1 to 3) | 2 (1 to 4) | 2 (1 to 3) | 2 (0 to 6) |
| 1 Month after 3rd vaccination-44/76-SL | 100 (99 to 100) | 100 (99 to 100) | 99 (98 to 100) | 100 (99 to 100) | 1 (0.022 to 5) |
| 5/99 (Baseline) | 3 (1 to 5) | 3 (1 to 5) | 2 (1 to 4) | 3 (2 to 4) | 2 (0 to 6) |
| 1 Month after 3rd vaccination-5/99 | 100 (99 to 100) | 100 (99 to 100) | 99 (98 to 100) | 100 (99 to 100) | 2 (0 to 6) |
| NZ98/254 (Baseline) | 1 (0.063 to 2) | 1 (0 to 3) | 0 (0 to 1) | 1 (0 to 1) | 0 (0 to 3) |
| 1 Month after 3rd vaccination | 70 (66 to 75) | 70 (65 to 74) | 75 (70 to 79) | 72 (69 to 74) | 1 (0.021 to 5) |
The safety and tolerability of three doses of rMenB+OMV NZ when given concomitantly with routine infant vaccines at 2, 4 and 6 months of age was assessed by the number of subjects reporting solicited local and systemic adverse events.
| Participants | rMenB All | MenC+Routine |
|---|---|---|
| Any Local | 2388 | 443 |
| Injection site tenderness | 2147 | 266 |
| Injection site erythema | 2049 | 261 |
| Injection site induration | 1908 | 227 |
| Injection site swelling | 1174 | 84 |
| Any Systemic | 2450 | 459 |
| Change in Eating Habits | 1787 | 257 |
| Sleepiness | 2159 | 353 |
| Vomiting | 662 | 116 |
| Diarrhea | 1086 | 164 |
| Irritability | 2296 | 370 |
| Unusual Crying | 2109 | 352 |
| Rash | 318 | 43 |
| Fever >= 38.5C | 1912 | 228 |
| Others | 2302 | 325 |
| Medical Attend. Fever | 57 | 16 |
| Analg. Antipyretic Med.Used | 2302 | 325 |
| Antipyretic Med.Used | 2240 | 314 |
Collected over All serious adverse events and medically attended adverse events are collected from Day 8 after each vaccination to next vaccination or to 30 days after the last vaccination.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| rMenB Lot1 | — | 70/832 (8.4%) | 827/832 (99.4%) |
| rMenB Lot2 | — | 80/828 (9.7%) | 825/828 (99.6%) |
| rMenB Lot3 | — | 60/820 (7.3%) | 817/820 (99.6%) |
| Routine | — | 51/659 (7.7%) | 652/659 (98.9%) |
| MenC+Routine | — | 28/490 (5.7%) | 482/490 (98.4%) |
| Event | rMenB Lot1 | rMenB Lot2 | rMenB Lot3 | Routine | MenC+Routine |
|---|---|---|---|---|---|
| BronchitisInfections and infestations | 6/832 | 12/828 | 7/820 | 11/659 | 1/490 |
| GastroenteritisInfections and infestations | 12/832 | 7/828 | 12/820 | 7/659 | 2/490 |
| LaryngitisInfections and infestations | 7/832 | 4/828 | 3/820 | 3/659 | 0/490 |
| Otitis mediaInfections and infestations | 3/832 | 2/828 | 6/820 | 3/659 | 0/490 |
| PyelonephritisInfections and infestations | 1/832 | 3/828 | 6/820 | 2/659 | 0/490 |
| Urinary tract infectionInfections and infestations | 2/832 | 0/828 | 1/820 | 0/659 | 3/490 |
| BronchiolitisInfections and infestations | 4/832 | 2/828 | 5/820 | 0/659 | 2/490 |
| BronchopneumoniaInfections and infestations | 1/832 | 4/828 | 1/820 | 1/659 | 0/490 |
| Gastroenteritis rotavirusInfections and infestations | 3/832 | 4/828 | 1/820 | 1/659 | 2/490 |
| PneumoniaInfections and infestations | 3/832 | 4/828 | 3/820 | 2/659 | 1/490 |
| Event | rMenB Lot1 | rMenB Lot2 | rMenB Lot3 | Routine | MenC+Routine |
|---|---|---|---|---|---|
| IrritabilityPsychiatric disorders | 769/832 | 761/828 | 766/820 | 544/659 | 370/490 |
| Injection site painGeneral disorders | 736/832 | 736/828 | 728/820 | 415/659 | 358/490 |
| Injection site erythemaGeneral disorders | 729/832 | 733/828 | 704/820 | 497/659 | 385/490 |
| SomnolenceNervous system disorders | 714/832 | 729/828 | 716/820 | 476/659 | 353/490 |
| CryingGeneral disorders | 714/832 | 711/828 | 685/820 | 424/659 | 352/490 |
| Injection site indurationGeneral disorders | 692/832 | 680/828 | 664/820 | 452/659 | 390/490 |
| PyrexiaGeneral disorders | 656/832 | 646/828 | 643/820 | 319/659 | 248/490 |
| Eating disorderPsychiatric disorders | 588/832 | 603/828 | 596/820 | 329/659 | 257/490 |
| Injection site swellingGeneral disorders | 440/832 | 466/828 | 436/820 | 254/659 | 184/490 |
| DiarrhoeaGastrointestinal disorders | 370/832 | 380/828 | 368/820 | 225/659 | 168/490 |
| Age, Continuous(Days) | rMenB Lot1 | rMenB Lot2 | rMenB Lot3 | Routine | MenC+ Routine | Total |
|---|---|---|---|---|---|---|
| Mean | 73.8 ± 9.5 | 74.1 ± 9.6 | 73.3 ± 9.4 | 74.7 ± 9.3 | 70.6 ± 9.7 | 73.5 ± 9.5 |
| Sex: Female, Male(Participants) | rMenB Lot1 | rMenB Lot2 | rMenB Lot3 | Routine | MenC+ Routine | Total |
|---|---|---|---|---|---|---|
| Female | 403 | 400 | 416 | 318 | 234 | 1771 |
| Male | 430 | 428 | 404 | 341 | 256 | 1859 |
The record gives a start of Mar 2008, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2015, 5 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.